Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > History will tell you, this is the time to.....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(48)
•••
Comment by snootchybootchyon Aug 04, 2016 3:46am
144 Views
Post# 25108954

RE:RE:RE:RE:RE:RE:RE:RE:History will tell you, this is the time to.....

RE:RE:RE:RE:RE:RE:RE:RE:History will tell you, this is the time to.....
Floridas2000 wrote: His particular statement is that CVS not selling Vimovo in the US will break Aralez.  That's just wrong, there are many other things that can break Aralez but that one event is not it.  The second part was that Tribute now becomes a non-contributor because of it.  That's also wrong.  Tribute was doing much better than Pozen before the merger and you can argue that Pozen's merger halted Tribute's progress where the share price was improving by multiples.

Now am I disappointed, absolutely.  The majority of the sector is very disappointing.  I don't want to bicker as well and BigBoy you've expressed concern about this for a long time and I've listened because you have elements of truth but some of what Select was saying wasn't true.

We need to be patient and see how Yosprala shakes out.  Anything until that is pointless.


Turns out this argument has become moot as Vimovo will now be covered by CVS/Caremark beginning on January 1, 2017.  Here is the link.  That may explain the large volume the other day?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities